Adjuvant hormonal therapy for stage I endometrial cancer

Current Oncology

Volumn 15, Issue 3, 2008, Pages 11-20

  Gien, Lilian ^a,c   Kwon, J ^b   Oliver, T K ^c   Fung Kee Fung, M ^d  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Adjuvant hormonal therapy; Early stage endometrial cancer; Stage 1 endometrial cancer

Indexed keywords

GESTAGEN; GESTONORONE CAPROATE; HYDROXYPROGESTERONE ACETATE; HYDROXYPROGESTERONE CAPROATE; MEDROXYPROGESTERONE ACETATE; PLACEBO; TAMOXIFEN;

ABDOMINAL HYSTERECTOMY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; EMBASE; ENDOMETRIUM CARCINOMA; HUMAN; HYPERTENSION; INFORMATION RETRIEVAL; LOADING DRUG DOSE; MEDLINE; NAUSEA; PERIPHERAL EDEMA; PREOPERATIVE RADIOTHERAPY; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; SALPINGOOOPHORECTOMY; SECOND CANCER; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 54349100998     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v15i3.204     Document Type: Review

References (15)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto: Canadian Cancer Society; 2006.
2. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 2003;83(suppl 1): 79-118.
3. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet 2005;366:491-505.
4. Lukka H, Chambers A, Fyles A, et al. Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review. Gynecol Oncol 2006;102:361-8.
5. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T, on behalf of the Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Systematic review of systemic therapy for advaced or recurrent endometrial cancer. Gynecol Oncol 2006;101:158-67.
6. von Minckwitz G, Loibl S, Brunnert K, et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer - a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 2002;38:2265-71.
7. Quinn MA. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. Int J Gynecol Cancer 1998;8:387-91.
8. Urbanski K, Karolewski K, Kojs Z, Klimek M, Dyba T. Adjuvant progestagen therapy improves survival in patients with endometrial cancer after hysterectomy. Results of one-institutional prospective clinical trial. Eur J Gynaecol Oncol 1993;14(suppl):98-104.
9. De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer. 1993;29A:1133-40.
10. Vergote I, Kjell K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64:1011-16.
11. Macdonald RR, Thorogood J, Mason MK. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 1988;95:166-74.
12. De Palo G, Spatti GB, Bandieramonte G, Luciani L. Pilot study with adjuvant hormone therapy in FIGO stage I endometrial carcinoma with myometrial invasion. Tumori 1983;69:65-7.
13. Malkasian GD Jr, Bur's J. Adjuvant progesterone therapy for stage I endometrial carcinoma. Int J Gynaecol Obstet 1978;16:48-9.
14. Lewis GC, Slack NH, Mortel R, Bross I. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 1974;2:368-76.
15. Martin-Hirsch PL, Jarvis G, Kitchener H, Lilford R. Progestagens for endometrial cancer. Cochrane Database Syst Rev 2000;(2):CD001040.